

AperTO - Archivio Istituzionale Open Access dell'Università di Torino

Impact of atrial fibrillation catheter ablation on mortality, stroke, and heart failure hospitalizations: A meta-analysis

This is the author's manuscript

Original Citation:

Availability:

This version is available <http://hdl.handle.net/2318/1769858> since 2021-01-28T16:56:03Z

Published version:

DOI:10.1111/jce.14429

Terms of use:

Open Access

Anyone can freely access the full text of works made available as "Open Access". Works made available under a Creative Commons license can be used according to the terms and conditions of said license. Use of all other works requires consent of the right holder (author or publisher) if not exempted from copyright protection by the applicable law.

(Article begins on next page)

1 **Impact of atrial fibrillation catheter ablation on**
2 **mortality, stroke and heart failure hospitalizations: a**
3 **meta-analysis.**

4
5 Andrea Saglietto, M.D.^{1*}; Roberto De Ponti, Prof., M.D.²; Luigi Di Biase, Prof., M.D., PhD;³ Mario
6 Matta, M.D.⁴; Fiorenzo Gaita, Prof., M.D.⁵, Jorge Romero, M.D.³; Gaetano Maria De Ferrari, Prof.,
7 M.D.¹; Matteo Anselmino, Prof., M.D., PhD¹

8
9 ¹ Division of Cardiology, Department of Medical Sciences, Città della Salute e della Scienza di
10 Torino, University of Turin, Italy.

11 ² Department of Heart and Vessels, Ospedale di Circolo & Macchi Foundation, University of
12 Insubria, Varese, Italy.

13 ³ Montefiore Medical Center, Albert-Einstein College of Medicine, Bronx, NY, USA.

14 ⁴ Division of Cardiology, Sant'Andrea Hospital, Vercelli, Italy.

15 ⁵ Cardiovascular Department, Clinica Pinna Pintor, Policlinico di Monza, Turin, Italy.

16 * Corresponding author: Andrea Saglietto; address: corso Dogliotti 14, 10126, Torino, Italy;
17 telephone number: (39)-0116709598; fax: (39)-0112369598; email address:
18 andrea.saglietto@live.com

19 Total word count: 2212

20 Conflict of interests:

21 Prof. Anselmino is consultant for Biosense Webster and has received lecture fees from Biosense
22 Webster and Abbott; Prof. De Ponti has received lecture fees from Biosense Webster and Biotronik;
23 Prof. Di Biase is a consultant for Stereoaaxis Biosense Webster, Boston Scientific, and St. Jude
24 Medical and has received speaker honoraria/travel support from Medtronic, Atricure, EPiEP, and
25 Biotronik.

26
27 Funding: none

1 **Abstract**

2 **Background** The impact of atrial fibrillation (AF) catheter ablation (CA) on hard clinical endpoints
3 remains controversial.

4 **Objective** Our aim was to conduct a random effect model meta-analysis on efficacy data from high-
5 quality large matched database/registry studies and randomized clinical trials. We compared long-
6 term all-cause mortality, stroke and hospitalization for heart failure in patients undergoing AFCA vs
7 patients treated with medical therapy alone (rhythm and/or rate control medications) in a general
8 AF population.

9 **Methods and Results** PubMed/MEDLINE and Embase databases were screened and a total of nine
10 studies were selected (one randomized clinical trial – CABANA – and eight large matched
11 population studies). A total of 241,372 patients (27,711 in the ablation group, 213,661 in the non-
12 ablation group) were included. After a median follow-up of 3.5 years, AFCA decreased the risk of
13 mortality (HR 0.62, 95% CI 0.54-0.72; $I^2 = 54%$; number needed to treat – NNT = 28), stroke (HR
14 0.63, 95% CI 0.56-0.70; $I^2 = 23%$; NNT 59) and hospitalization for heart failure (HR 0.64, 95% CI
15 0.51-0.80; $I^2 = 28%$; NNT = 33) compared with AF patients treated with medical therapy alone.

16 **Conclusion** Based on the currently available efficacy and effectiveness evidence, AFCA
17 significantly reduces the risk of death, stroke and hospitalization compared to medical therapy
18 alone.

19

20 **Keywords:** atrial fibrillation; catheter ablation; all-cause mortality, stroke, hard clinical outcomes.

21

1 **Abbreviations and acronyms**

2 AADs = anti-arrhythmic drugs

3 ACR = assumed control risk

4 AF = atrial fibrillation

5 AFCA = atrial fibrillation catheter ablation

6 ARR = absolute risk reduction

7 CI = confidence interval

8 HR = hazard ratio

9 NNT = number needed to treat

10 RCT = randomized clinical trial

11 TIA = transient ischemic attack

12

1 Introduction

2 Atrial fibrillation (AF) is the most common arrhythmia encountered in clinical practice, with a
3 progressively growing burden due to population aging. Sinus rhythm maintenance (rhythm control),
4 reflecting the native heart rhythm, may be perceived as the most natural solution compared to just
5 controlling ventricular rate (rate control). However, in terms of prevention of death, stroke and heart
6 failure, rate control has been proven to be non-inferior to rhythm control with anti-arrhythmic drugs
7 (AADs) in pivotal clinical trials ^{1,2}. This is most likely explained by the side effects and pro-
8 arrhythmic effects related to AADs, together with a relatively low efficacy of these agents in
9 maintaining sinus rhythm.

10 Atrial fibrillation catheter ablation (AFCA) has emerged in clinical practice; although few
11 randomized clinical studies ^{3,4} have reported promising outcomes in terms of sinus rhythm
12 maintenance and safety when compared to AADs, they have singularly failed to demonstrate a
13 statistically significant impact of the procedure on hard outcomes (mortality, stroke or HF
14 hospitalization). These studies have however been widely debated, being generally underpowered to
15 reveal a possible impact on the aforementioned outcomes in patients undergoing AFCA ⁵ or
16 affected by crossovers between the study arms ⁶. On the contrary, evidence from observational
17 matched databases/registry studies suggest a net benefit of AFCA in terms of hard clinical endpoint
18 reductions ^{7,8}.

19 The present meta-analysis aimed to determine whether AFCA is effective and safe in the general
20 AF population by assessing its long-term impact on mortality, stroke and hospitalization due to
21 heart failure decompensation.

22

23

1 **Methods**

2 The present systematic review and meta-analysis were performed in accordance to PRISMA⁹ and
3 MOOSE guidelines¹⁰.

5 **Search strategy**

6 We screened PubMed/MEDLINE and Embase databases from their inceptions to April 30th 2019,
7 using the following search terms: (atrial fibrillation OR AF) AND (catheter ablation OR AFCA OR
8 ablation) AND (Mortality OR death OR stroke OR CVA OR hospitalization) AND (database OR
9 registry OR registries OR databases OR RCT).

10

11 **Study selection and quality assessment**

12 Two investigators (A.S., M.A.) independently reviewed the titles/abstracts and studies to determine
13 their eligibility based on the inclusion criteria and extracted all the relevant outcomes of interest.

14 Randomized and non-randomized studies were eligible for inclusion if they (a) compared at least
15 one hard clinical outcome (mortality, stroke and, since AF is known to mimic heart failure
16 symptoms and/or trigger heart failure episodes, hospitalization for heart failure) between cohorts of
17 ablated and non-ablated AF patients (in case of registry studies, only if they provided adjusted risk
18 estimates); (b) reported risk estimates for the investigated outcomes based on *time-to-event* data
19 (hazard ratio – HR); (c) had a median follow-up of at least 2 years, thus focusing on studies
20 evaluating long-term impact of AFCA on hard clinical outcomes; (d) did not exclusively include
21 patients with impaired left ventricular ejection fraction.

22 Risk of bias assessment was performed at the study level using the Cochrane bias risk assessment
23 tool for RCT and the Newcastle-Ottawa Scale (NOS) for observational studies (Appendix).

24

1 **Statistical analysis**

2 Baseline characteristics of pooled study populations were reported as median values between the
3 included studies, along with their interquartile range.

4 Due to the observational nature of most of the studies, a random effect model (inverse-variance
5 weighting) was adopted. Random effect model meta-analysis gives more conservative estimates
6 with respect to fixed effect model meta-analysis, since, differently from fixed effect model, it takes
7 into account the estimated between-study heterogeneity when pooling individual study results.

8 Meta-analysis of hazard ratio (HR) was performed after logarithmic transformation. The results
9 with the corresponding 95% confidence interval (CI) were back-transformed and forest plots for the
10 different outcomes were generated. To investigate potential publication bias, Egger test was used to
11 identify asymmetry of funnel plot. Heterogeneity across studies was assessed using the Cochran Q
12 test. Higgins I^2 statistics was used to determine the degree of between-study heterogeneity
13 ($I^2 < 25\%$ —low, 25–50%—moderate, and $>50\%$ —high degree of heterogeneity). In case of high
14 degree of heterogeneity, meta-regression analysis was performed to assess potential source of
15 heterogeneity.

16 For each outcome, absolute risk reduction was calculated by multiplying the meta-analytic HR
17 (with the corresponding CI) by the assumed control risk (ACR) obtained from the meta-analysis of
18 the incidence rate of the outcome (expressed as events/person years) in non-ablation cohorts
19 (Appendix, Figure 1). Number needed to treat (NNT) was derived by dividing 1 by the calculated
20 absolute risk reduction (ARR), and the resulting number was finally divided by the meta-analytic
21 median follow-up in order to obtain an estimate normalized to follow-up duration.

22 P values < 0.05 were considered statistically significant. Statistical analyses were performed with R
23 version 3.5.0 (R Foundation for Statistical Computing, Vienna, Austria).

24

1 Results

2 The initial search, by the specified search criteria, identified 1,187 potential studies (Figure 1).

3 After detailed evaluation, 19 publications were eligible for possible inclusion and, therefore, full
4 texts reviewed. Four RCTs were excluded since they were specifically conducted in the setting of
5 heart failure¹¹⁻¹⁴. Four RCTs were excluded since they did not provide *time-to-event* risk estimates
6 (hazard ratio) for the investigated outcomes¹⁵⁻¹⁸. One large registry study was excluded due to the
7 indirect nature of the comparison between the ablation and non-ablation cohort¹⁹, while a second
8 was discarded since it did not provide confidence intervals for the adjusted risk estimates of
9 mortality and stroke²⁰.

10 Finally, 9 studies (one RCT – CABANA – and eight large matched population databases/registries)
11 were included in the analysis^{6, 8, 21-28}, encompassing 241,372 patients (27,711 in the ablation group,
12 213,661 in the non ablation-group), with a median follow-up of 3.5 years (Table 1). The baseline
13 clinical features of the resulting meta-analytic population are summarized in Table 2. Median age
14 was 64.1 years, with nearly 2:1 male-to-female ratio. The most frequent concurrent comorbid
15 conditions were hypertension (55.0%), diabetes (17.0%) and coronary artery disease (19.2%).
16 Baseline heart failure was present in a low percentage of patients (15.3%). A median of 5.2%
17 patients suffered previous stroke/TIA and 69.8% had high thromboembolic risk (CHA₂DS₂-VASc
18 score ≥ 2). CABANA population, with respect to the pooled population derived from non-
19 randomized matched databases, resulted slightly older, with more comorbid conditions and a higher
20 baseline thromboembolic risk (Table 2). The statistical methods to control confounding in non-
21 randomized matched database are reported in Table 1: 5 studies used propensity score matching, 2
22 other propensity score techniques (adjustment and weighting) and 1 study used multivariate
23 regression analysis.

24 By random effect model meta-analysis, AFCA decreased the risk of mortality (HR 0.62, 95% CI
25 0.54-0.72; I² = 54%; NNT 28), stroke (HR 0.63, 95% CI 0.56-0.70; I² = 23%; NNT 59) and

1 hospitalization for heart failure (HR 0.64, 95% CI 0.51-0.80; I2 = 28%; NNT 33) compared with
2 medically-treated AF patients. One-year estimated absolute risk reduction in mortality, stroke and
3 hospitalization for heart failure were 1%, 0.5% and 0.8%, respectively.
4 There was no evidence of publication bias for the outcomes of interest (Egger's test p value 0.28,
5 0.65 and 0.46, respectively; funnel plots are reported in the Appendix, Figures 3-5). Significant
6 heterogeneity was only present in the mortality estimate. Meta-regression analyses excluded
7 baseline heart failure (p=0.316) as potential source of heterogeneity, while increased age was
8 significantly associated with a reduced benefit from ablation (p=0.004, Appendix Figure 2).
9 Considering "treatment received" rather than "intention to treat" analysis from CABANA data,
10 catheter ablation decreased the risk of mortality by a greater extent (HR 0.60, 95% CI 0.53-0.67; I2
11 = 29%), with a decrease in the estimated heterogeneity (Figure 4).

12
13
14

1 Discussion

2 In the present meta-analysis, AFCA was more effective than medical therapy in reducing hard
3 clinical endpoints, providing a 38% decrease in mortality, 37% decrease in stroke and 36%
4 reduction in heart failure hospitalization over a median follow-up of 3.5 years.

5 AFCA is currently a rhythm control option in AF patients who remain symptomatic on adequate
6 rate control therapy. Conversely, the proven increased efficacy in maintaining sinus rhythm and
7 safety of AFCA compared to AADs prompts questions regarding a possible favorable prognostic
8 impact of modern rhythm control strategy, either with AFCA alone or with an hybrid approach
9 (AFCA+AADs). The Catheter Ablation for Atrial Fibrillation with Heart Failure (CASTLE-AF)
10 Trial ¹¹ confirmed previous meta-analytic impressions ²⁹, showing that in patients with heart failure,
11 AFCA reduced the primary endpoint of all-cause-death or hospitalization compared with medical
12 therapy. Differently, in patients without heart failure, a meta-analysis comparing AFCA vs medical
13 therapy on published RCTs apparently found no difference in survival between these two strategies
14 ⁵. However, it should be noted that, in the latter analysis, the included studies were only four,
15 underpowered for detecting differences in survival (low number of enrolled patients), the follow-up
16 duration was short (9 to 24 months, median 12 months) and, most importantly, the number of events
17 investigated extremely low (6 and 7, in the pooled ablation and medical therapy cohorts,
18 respectively). Recently, Barra et al. ³⁰ also investigated the topic either in RCTs and observational
19 studies. In their analysis, the authors found a survival benefit of AFCA, but the randomized
20 evidence was driven by studies performed specifically in the HF setting, concluding that more data
21 are needed to draw conclusions in the general AF population. More specifically regarding risk of
22 stroke, a benefit was only seen within the observational studies, while no benefit emerged
23 considering randomized evidences (however, only 32 stroke events in the pooled cohorts were seen
24 during the follow-up).

25 In addition, inclusion of the latest, widest randomized clinical trial surely increases available

1 knowledge. The CABANA trial ⁶, in the “intention to treat” analysis, reported no significant
2 differences neither in the primary outcome (composite of death, disabling stroke, serious bleeding,
3 or cardiac arrest), nor in mortality between AFCA and medical therapy groups. This result,
4 however, was likely affected by a significant lower-than-expected overall mortality rate (from the
5 expected 12% after 3 years to the actual 5% after 4 year) and high treatment crossover (27.5% from
6 drug therapy to ablation). Moreover, the composite primary outcome of CABANA trial included
7 bleeding and stroke, which AFCA has no impact on. In fact, as stated by the authors, definitive
8 conclusions cannot be drawn, especially considering that, on the other side, “treatment received”
9 analysis suggested a significant reduction in mortality in the AFCA group of 40% (HR 0.60, 95%
10 CI 0.42-0.80).

11 Given these premises, our aim was to synthesize high-quality RCT data of AFCA *efficacy* (deriving
12 from CABANA) with real-life evidence of AFCA *effectiveness* (provided by large registry studies),
13 in terms of hard clinical endpoints (mortality, stroke and hospitalization for heart failure) in a
14 general AF population. In this sense, our meta-analysis is different from the meta-analysis of Barra
15 et al. ³⁰ since (1) it excludes studies exclusively enrolling HF patients, in order to draw general
16 conclusions in the general AF population; (2) it includes the greatest randomized evidence
17 published so far in the context of AF (CABANA trial ⁶); (3) it includes recently released
18 observational data not included in the previous meta-analysis ^{27,28}.

19 The meta-analytic estimates indicate that AFCA significantly reduces all three hard clinical
20 endpoints by nearly 40%. The heterogeneity of the data was high only for mortality ($I^2 = 63\%$).
21 Interestingly, older age was associated with a decrease in AFCA benefit and thus could explain, at
22 least partly, the increased heterogeneity of the data. Considering “treatment received” instead of
23 “intention to treat” analysis from CABANA, we appreciated a drop in the total heterogeneity of
24 mortality data and an increase in the benefit of AFCA. Of note, the *efficacy* estimate deriving from
25 patients that actually underwent ablation in CABANA (HR 0.60, 95% CI 0.42-0.80) is highly
26 comparable to the meta-analytic *effectiveness* pooled estimate of mortality reduction in AFCA

1 group for the registry studies (HR 0.60, 95% CI 0.53-0.68; $I^2 = 43\%$).
2 Additional information is conveyed by the calculated NNTs for each outcome of interest, which not
3 only take into account the magnitude of the benefit of the intervention, but also depend on the rate
4 of the specific endpoint in the study population. Despite a similar HR for the three outcomes, NNTs
5 differed between stroke (NNT 59) and the other two endpoints (NNT 28 for mortality, NNT 33 for
6 hospitalization), reflecting the different pooled incidence rates in the medically treated group
7 (mortality: 2.70 events/100 person-years; stroke: 1.32 events/100 person-years; hospitalization for
8 heart failure: 2.41 events/100 person-years) (Figure 4). In this sense, considering the high
9 proportion of patients in the included meta-analysis at high thromboembolic risk (CHA₂DS₂-VASC
10 score > 2: 69.8%), the relatively more limited impact of AFCA on incidence rate of stroke,
11 compared to the other outcomes, probably reflects the effective anticoagulation strategy of the
12 medical arm.

13 In this context, awaiting publication of the Early treatment of Atrial fibrillation for Stroke
14 prevention (EAST) Trial (ClinicalTrial.gov Identifier: NCT01288352), the present meta-analyses
15 summarizes the latest *efficacy* evidence from CABANA and real-world *effectiveness* data derived
16 from observational registries comparing AFCA with medical therapy, suggesting promising effects
17 of the electrophysiological procedure not only in preventing AF recurrences but also in improving
18 long-term prognosis of AF patients.

19

20 **Limitations**

21 First, this study is limited by the heterogeneity of study participants and outcome definitions
22 between different studies. Moreover, retrospective registry data should be interpreted with caution,
23 due to their observational nature. Even though matching and multivariable analysis can control
24 known confounders, residual confounding attributable to unmeasured factors remains a concern. In
25 addition, retrospective registry data often lacked information regarding the type of AF (paroxysmal

1 vs persistent) and arrhythmia duration of the included patients, thus precluding possible subgroup
2 meta-analyses. Finally, it is possible that studies shorter than two years, excluded since the focus of
3 the present analysis on long-term outcomes, may have contributed additional patients and power to
4 detect differences in investigated outcomes that may manifest within the first two post-procedural
5 years.

6

1 **Conclusion**

2 In the present meta-analysis, based on the CABANA trial and data from eight large matched
3 registries, AFCA significantly reduces the risk of death, stroke and hospitalization for heart failure
4 compared to medical therapy alone (AADs and/or rate control drugs).

5

1 **Acknowledgments**

2

3 None.

4

5

References

- [1] Wyse DG, Waldo AL, DiMarco JP, Domanski MJ, Rosenberg Y, Schron EB, Kellen JC, Greene HL, Mickel MC, Dalquist JE, Corley SD, Atrial Fibrillation Follow-up Investigation of Rhythm Management I: A comparison of rate control and rhythm control in patients with atrial fibrillation. *The New England journal of medicine* 2002; 347:1825-1833.
- [2] Van Gelder IC, Hagens VE, Bosker HA, Kingma JH, Kamp O, Kingma T, Said SA, Darmanata JI, Timmermans AJ, Tijssen JG: A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. *New England Journal of Medicine* 2002; 347:1834-1840.
- [3] Wazni OM, Marrouche NF, Martin DO, Verma A, Bhargava M, Saliba W, Bash D, Schweikert R, Brachmann J, Gunther J: Radiofrequency ablation vs antiarrhythmic drugs as first-line treatment of symptomatic atrial fibrillation: a randomized trial. *Jama* 2005; 293:2634-2640.
- [4] Mont L, Bisbal F, Hernández-Madrid A, Pérez-Castellano N, Viñolas X, Arenal A, Arribas F, Fernández-Lozano I, Bodegas A, Cobos A: Catheter ablation vs. antiarrhythmic drug treatment of persistent atrial fibrillation: a multicentre, randomized, controlled trial (SARA study). *European heart journal* 2013; 35:501-507.
- [5] Khan SU, Rahman H, Talluri S, Kaluski E: The clinical benefits and mortality reduction associated with catheter ablation in subjects with atrial fibrillation: a systematic review and meta-analysis. *JACC: Clinical Electrophysiology* 2018; 4:626-635.
- [6] Packer DL, Mark DB, Robb RA, Monahan KH, Bahnson TD, Poole JE, Noseworthy PA, Rosenberg YD, Jeffries N, Mitchell LB, Flaker GC, Pokushalov E, Romanov A, Bunch TJ, Noelker G, Ardashev A, Revishvili A, Wilber DJ, Cappato R, Kuck K-H, Hindricks G, Davies DW, Kowey PR, Naccarelli GV, Reiffel JA, Piccini JP, Silverstein AP, Al-Khalidi HR, Lee KL, for the CI: Effect of Catheter Ablation vs Antiarrhythmic Drug Therapy on Mortality, Stroke, Bleeding, and Cardiac Arrest Among Patients With Atrial Fibrillation: The CABANA Randomized Clinical Trial. *Effect of Catheter Ablation vs Antiarrhythmic Drugs on Mortality, Stroke, Bleeding, and Cardiac Arrest in AF*. 2019.
- [7] Kalman JM, Sanders P, Rosso R, Calkins H: Should we perform catheter ablation for asymptomatic atrial fibrillation? *Circulation* 2017; 136:490-499.
- [8] Noseworthy PA, Gersh BJ, Kent DM, Piccini JP, Packer DL, Shah ND, Yao X: Atrial fibrillation ablation in practice: assessing CABANA generalizability. *European heart journal* 2019.
- [9] Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D: The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. *PLoS medicine* 2009; 6:e1000100.
- [10] Higgins J: *Cochrane handbook for systematic reviews of interventions version 5.0. 2* (updated September 2009). The Cochrane Collaboration. <http://www.Cochrane-handbook.org> 2009.
- [11] Marrouche NF, Brachmann J, Andresen D, Siebels J, Boersma L, Jordaens L, Merkely B, Pokushalov E, Sanders P, Proff J: Catheter ablation for atrial fibrillation with heart failure. *New England Journal of Medicine* 2018; 378:417-427.
- [12] Di Biase L, Mohanty P, Mohanty S, Santangeli P, Trivedi C, Lakkireddy D, Reddy M, Jais P, Themistoclakis S, Dello Russo A: Ablation versus amiodarone for treatment of persistent atrial fibrillation in patients with congestive heart failure and an implanted device: results from the AATAC multicenter randomized trial. *Circulation* 2016; 133:1637-1644.

- 1 [13] Hunter RJ, Berriman TJ, Diab I, Kamdar R, Richmond L, Baker V, Goromonzi F, Sawhney
2 V, Duncan E, Page SP: A randomized controlled trial of catheter ablation versus medical
3 treatment of atrial fibrillation in heart failure (the CAMTAF trial). *Circulation: Arrhythmia and*
4 *Electrophysiology* 2014; 7:31-38.
- 5 [14] Jones DG, Haldar SK, Hussain W, Sharma R, Francis DP, Rahman-Haley SL, McDonagh
6 TA, Underwood SR, Markides V, Wong T: A randomized trial to assess catheter ablation versus
7 rate control in the management of persistent atrial fibrillation in heart failure. *Journal of the*
8 *American College of Cardiology* 2013; 61:1894-1903.
- 9 [15] Jaïs P, Cauchemez B, Macle L, Daoud E, Khairy P, Subbiah R, Hocini M, Extramiana F,
10 Sacher F, Bordachar P: Catheter ablation versus antiarrhythmic drugs for atrial fibrillation:
11 the A4 study. *Circulation* 2008; 118:2498-2505.
- 12 [16] Cosedis Nielsen J, Johannessen A, Raatikainen P, Hindricks G, Walfridsson H, Kongstad
13 O, Pehrson S, Englund A, Hartikainen J, Mortensen LS: Radiofrequency ablation as initial
14 therapy in paroxysmal atrial fibrillation. *New England Journal of Medicine* 2012; 367:1587-
15 1595.
- 16 [17] Stabile G, Bertaglia E, Senatore G, De Simone A, Zoppo F, Donnici G, Turco P, Pascotto P,
17 Fazzari M, Vitale DF: Catheter ablation treatment in patients with drug-refractory atrial
18 fibrillation: a prospective, multi-centre, randomized, controlled study (Catheter Ablation For
19 The Cure Of Atrial Fibrillation Study). *European heart journal* 2005; 27:216-221.
- 20 [18] Wilber DJ, Pappone C, Neuzil P, De Paola A, Marchlinski F, Natale A, Macle L, Daoud EG,
21 Calkins H, Hall B: Comparison of antiarrhythmic drug therapy and radiofrequency catheter
22 ablation in patients with paroxysmal atrial fibrillation: a randomized controlled trial. *Jama*
23 2010; 303:333-340.
- 24 [19] Hunter RJ, McCready J, Diab I, Page SP, Finlay M, Richmond L, French A, Earley MJ,
25 Sporton S, Jones M: Maintenance of sinus rhythm with an ablation strategy in patients with
26 atrial fibrillation is associated with a lower risk of stroke and death. *Heart* 2011:heartjnl-
27 2011-300720.
- 28 [20] Bunch TJ, Crandall BG, Weiss JP, May HT, Bair TL, Osborn JS, Anderson JL, Muhlestein
29 JB, Horne BD, Lappe DL: Patients treated with catheter ablation for atrial fibrillation have
30 long - term rates of death, stroke, and dementia similar to patients without atrial fibrillation.
31 *Journal of cardiovascular electrophysiology* 2011; 22:839-845.
- 32 [21] Reynolds MR, Gunnarsson CL, Hunter TD, Ladapo JA, March JL, Zhang M, Hao SC: Health
33 Outcomes With Catheter Ablation or Antiarrhythmic Drug Therapy in Atrial Fibrillation.
34 *Circulation: Cardiovascular Quality and Outcomes* 2012; 5:171-181.
- 35 [22] Chang C-H, Lin J-W, Chiu F-C, Caffrey JL, Wu L-C, Lai M-S: Effect of Radiofrequency
36 Catheter Ablation for Atrial Fibrillation on Morbidity and Mortality-A Nationwide Cohort
37 Study and Propensity-Score Analysis. *Circulation: Arrhythmia and Electrophysiology*
38 2014:CIRCEP. 113.000597.
- 39 [23] Karasoy D, Gislason GH, Hansen J, Johannessen A, Køber L, Hvidtfeldt M, Özcan C, Torp-
40 Pedersen C, Hansen ML: Oral anticoagulation therapy after radiofrequency ablation of atrial
41 fibrillation and the risk of thromboembolism and serious bleeding: long-term follow-up in
42 nationwide cohort of Denmark. *European heart journal* 2014; 36:307-315.
- 43 [24] Friberg L, Tabrizi F, Englund A: Catheter ablation for atrial fibrillation is associated
44 with lower incidence of stroke and death: data from Swedish health registries. *European heart*
45 *journal* 2016; 37:2478-2487.
- 46 [25] Saliba W, Schliamser JE, Lavi I, Barnett-Griness O, Gronich N, Rennert G: Catheter
47 ablation of atrial fibrillation is associated with reduced risk of stroke and mortality: A
48 propensity score-matched analysis. *Heart rhythm : the official journal of the Heart Rhythm*
49 *Society* 2017; 14:635-642.

1 [26] Joza J, Samuel M, Jackevicius CA, Behloul H, Jia J, Koh M, Tsadok MA, Tang AS, Verma A,
2 Pilote L: Long - term risk of stroke and bleeding post-atrial fibrillation ablation. Journal of
3 cardiovascular electrophysiology 2018; 29:1355-1362.

4 [27] Srivatsa UN, Xing G, Amsterdam E, Chiamvimonvat N, Pezeshkian N, Fan D, White RH:
5 CALifornia study of ABLation for Atrial Fibrillation: re-hospitalization for Cardiac Events
6 (CAABL-CE). Journal of atrial fibrillation 2018; 11.

7 [28] Srivatsa UN, Danielsen B, Amsterdam EA, Pezeshkian N, Yang Y, Nordsieck E, Fan D,
8 Chiamvimonvat N, White RH: CAABL-AF (California Study of Ablation for Atrial Fibrillation)
9 Mortality and Stroke, 2005 to 2013. Circulation: Arrhythmia and Electrophysiology 2018;
10 11:e005739.

11 [29] Anselmino M, Matta M, D'ascenzo F, Bunch TJ, Schilling RJ, Hunter RJ, Pappone C,
12 Neumann T, Noelker G, Fiala M: Catheter ablation of atrial fibrillation in patients with left
13 ventricular systolic dysfunction: a systematic review and meta-analysis. Circulation:
14 Arrhythmia and Electrophysiology 2014:CIRCEP. 114.001938.

15 [30] Barra S, Baran J, Narayanan K, Boveda S, Fynn S, Heck P, Grace A, Agarwal S, Primo J,
16 Marijon E: Association of catheter ablation for atrial fibrillation with mortality and stroke: A
17 systematic review and meta-analysis. International journal of cardiology 2018; 266:136-142.
18
19

1 **Figure legends**

2 **Figure 1. Flow-chart of the search strategy following PRISMA guidelines.** LVEF: left
3 ventricular ejection fraction; HR: hazard ratio.

4
5 **Figure 2. Meta-analysis forest plots.** Shown are random-effect hazard ratios for mortality
6 (a), stroke (b) and hospitalization for heart failure (c) in the included studies.

7
8 **Figure 3. Meta-analysis forest plot of mortality (considering treatment received
9 analysis of CABANA data).**

10
11 **Figure 4. Impact of atrial fibrillation catheter ablation on hard clinical outcomes.** PY:
12 person-years; NNT: number needed to treat.